Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E13.85 EPS (ttm)4.63 Insider Own0.70% Shs Outstand1.26B Perf Week0.20%
Market Cap80.85B Forward P/E9.22 EPS next Y6.95 Insider Trans-0.79% Shs Float1.26B Perf Month-1.43%
Income5.97B PEG6.06 EPS next Q1.72 Inst Own83.70% Short Float1.23% Perf Quarter-2.66%
Sales22.36B P/S3.62 EPS this Y-45.60% Inst Trans1.18% Short Ratio2.51 Perf Half Y-3.97%
Book/sh17.81 P/B3.60 EPS next Y-0.54% ROA9.40% Target Price80.80 Perf Year-15.19%
Cash/sh21.56 P/C2.97 EPS next 5Y2.29% ROE26.80% 52W Range60.32 - 79.61 Perf YTD2.49%
Dividend2.52 P/FCF18.85 EPS past 5Y18.10% ROI12.00% 52W High-19.92% Beta1.09
Dividend %3.93% Quick Ratio3.70 Sales past 5Y14.60% Gross Margin79.40% 52W Low5.69% ATR1.41
Employees11000 Current Ratio3.80 Sales Q/Q0.70% Oper. Margin37.70% RSI (14)41.64 Volatility1.43% 2.05%
OptionableYes Debt/Eq1.15 EPS Q/Q6.60% Profit Margin26.60% Rel Volume0.67 Prev Close64.11
ShortableYes LT Debt/Eq1.06 EarningsJul 30 AMC Payout51.60% Avg Volume6.18M Price63.76
Recom2.10 SMA20-1.91% SMA50-4.01% SMA200-4.00% Volume1,960,748 Change-0.55%
Jul-29-19Upgrade RBC Capital Mkts Outperform → Top Pick $91
Jul-15-19Upgrade Wells Fargo Market Perform → Outperform $68 → $88
May-28-19Downgrade Goldman Neutral → Sell
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Neutral $70
Apr-26-19Initiated Bernstein Outperform $82
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Aug-20-19 10:00AM  Flush with cash after Gilead deal, founder pivots to real estate for his companies American City Business Journals
10:00AM  DRRX: Gilead Agreement, Near-Term Value-Inflection Opportunities Make DRRX Particularly Attractive at Current Valuation Zacks Small Cap Research
Aug-19-19 01:50PM  5 Top ESG Stocks on RBC Capitalrsquo;s lsquo;Best Ideasrsquo; List Kiplinger
Aug-18-19 05:00AM  Gilead did not seek US exclusivity on PrEP with Truvada Financial Times
Aug-17-19 06:53PM  Stocks That Fell to 3-Year Lows in the Week of Aug. 16 GuruFocus.com
12:16PM  3 Dividend Stocks That Should Pay You the Rest of Your Life Motley Fool
Aug-16-19 09:19AM  Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe Zacks
Aug-15-19 05:27PM  Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future American City Business Journals
04:01PM  European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis Business Wire
08:00AM  Québec Provides Access to Biktarvy® for the Treatment of HIV CNW Group
Aug-14-19 09:21AM  Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More Zacks
08:34AM  Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Zacks
Aug-13-19 10:43AM  Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks
10:10AM  Is Gilead Sciences (GILD) a Great Stock for Value Investors? Zacks
Aug-12-19 08:41AM  What Kind Of Investor Owns Most Of Gilead Sciences, Inc. (NASDAQ:GILD)? Simply Wall St.
08:23AM  3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences InvestorPlace
Aug-11-19 09:00AM  3 Embarrassingly Cheap Dividend Stocks Motley Fool
Aug-09-19 11:11AM  Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss Zacks
11:09AM  Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat Zacks
09:27AM  Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates Zacks
09:00AM  Gilead's HIV drug Biktarvy approved in China MarketWatch
08:30AM  China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection Business Wire
Aug-08-19 10:00AM  Gilead Stock Is Among The Biggest Biotech Stocks But Should You Buy It? Investor's Business Daily
09:26AM  Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus Zacks
Aug-07-19 11:28PM  Medicare to cover expensive cancer cell therapies Reuters
08:44PM  Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committees Recommendation on Descovy for PrEP Business Wire
06:36PM  UPDATE 1-Medicare to cover expensive cancer cell therapies Reuters
05:39PM  UPDATE 1-FDA panel backs Gilead's HIV prevention drug Descovy, except in women Reuters
05:32PM  Medicare to cover cancer CAR-Ts therapies Reuters
04:43PM  FDA panel backs Gilead's HIV prevention drug for certain population Reuters
06:00AM  FOCUS-Patient groups push back against Gilead's pricey HIV prevention treatment Reuters
Aug-06-19 04:22PM  Biotech ETFs in Focus on Impressive Q2 Earnings Results Zacks
08:00AM  Ontario Provides Access to Biktarvy® for the Treatment of HIV CNW Group
Aug-05-19 01:08PM  Here's Why Galapagos NV Rose 34.5% in July Motley Fool
09:07AM  Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings? Zacks
Aug-03-19 01:15AM  Top Biotech Stocks for February 2019 Investopedia
Aug-02-19 05:09AM  Edited Transcript of GILD earnings conference call or presentation 30-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
Jul-31-19 04:15PM  5 Top Stock Trades for Thursday: GE, GILD, SPOT, EA InvestorPlace
11:36AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks
11:09AM  Are Amgen and Gilead Sciences Better Buys After Second-Quarter Earnings? Motley Fool
09:55AM  Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised Zacks
08:01AM  3 Charts Suggest Health Care Stocks Are Headed Higher Investopedia
07:00AM  Gilead Sciences Reports Improving Revenue in the 2nd Quarter Motley Fool
06:56AM  Gilead earnings show surprising sales increase amid massive change MarketWatch
04:25AM  Stocks - AMD, Spotify Fall Premarket; Apple Rises Investing.com
02:04AM  After Hours: Apple, Mastercard, and Gilead Sciences Report Earnings Motley Fool
Jul-30-19 05:25PM  Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates Zacks
05:13PM  How A Key Franchise Helped Gilead's Quarterly Sales To Inch Up Investor's Business Daily
05:05PM  Gilead Sciences Beats Second-Quarter Earnings Expectations Barrons.com
04:36PM  Gilead results beat Street estimates as demand grows for HIV drug Reuters
04:32PM  UPDATE 2-Gilead results beat Street estimates as demand grows for HIV drug Reuters
04:06PM  Gilead quarterly profit rises 3.5% Reuters
04:02PM  Gilead Sciences Announces Third Quarter 2019 Dividend Business Wire
04:01PM  Gilead Sciences Announces Second Quarter 2019 Financial Results Business Wire
02:30PM  Gilead Sciences, Inc. to Host Earnings Call ACCESSWIRE
01:52PM  Gilead and Amgen will report second-quarter earnings after the closing bell. Heres what to expect MarketWatch
01:14PM  Merck Shares Rise on Strong Sales Growth GuruFocus.com
07:02AM  Buy 6 Top Stocks Set to Beat on Earnings in Q2 Today Zacks
06:06AM  Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments Reuters
06:00AM  FOCUS-Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments Reuters
Jul-29-19 04:43PM  Marijuana Stock Cann('t)Trust, and What's Behind Gilead's Latest Megadeal Motley Fool
04:12PM  Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards? Zacks
02:07PM  RBC On Gilead: 'A Compelling Opportunity To Build A Long-Term Position' Benzinga
11:40AM  Axovant (AXGT) to Post Q1 Earnings: What's in the Cards? Zacks
11:08AM  Guardant Health (GH) to Report Q2 Earnings: What's in Store? Zacks
10:12AM  What's in Store for Array BioPharma (ARRY) in Q4 Earnings? Zacks
10:08AM  Health Care Digest: Kilroy's Oyster Point mystery, helping researchers ditch spreadsheets and more American City Business Journals
08:07AM  Here Are 8 Stocks to Watch This Week TheStreet.com
Jul-26-19 12:06PM  What's in the Cards for Pfizer (PFE) This Earnings Season? Zacks
11:50AM  Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings? Zacks
11:50AM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
11:49AM  Vertex (VRTX) to Post Q2 Earnings: What's in the Cards? Zacks
11:23AM  Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2? Zacks
10:03AM  Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings? Zacks
09:27AM  5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2 Zacks
Jul-25-19 11:10AM  Acorda (ACOR) to Post Q2 Earnings: What's in the Cards? Zacks
07:29AM  What's in the Cards for AcelRx (ACRX) This Earnings Season? Zacks
Jul-24-19 05:45PM  Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
10:58AM  Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded Zacks
09:30AM  Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? Zacks
09:04AM  Eli Lilly (LLY) to Report Q2 Earnings: What's in Store? Zacks
09:00AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Jul-23-19 11:26PM  GSK market hopes boosted by two-drug HIV trial Financial Times
04:00PM  Gilead Announces Latest Data in Ongoing HIV Cure Research Program Business Wire
02:47PM  5 Biotech Stocks to Buy for a Strong Growth Prognosis InvestorPlace
11:00AM  Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada® Business Wire
10:56AM  Is a Beat in Store for Repligen (RGEN) This Earnings Season? Zacks
10:32AM  Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
09:29AM  AMAG (AMAG) to Report Q2 Earnings: What's in the Cards? Zacks
03:03AM  3 Perfect 10 Biotech Stocks to Buy TipRanks
Jul-22-19 12:00PM  Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance Business Wire
11:13AM  What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings? Zacks
11:00AM  Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV Business Wire
10:55AM  Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy Zacks
10:16AM  Alexion (ALXN) to Report Q2 Earnings: What's in the Cards? Zacks
09:16AM  Is Gilead Sciences, Inc. (NASDAQ:GILD) A High Quality Stock To Own? Simply Wall St.
09:02AM  One Prescription for Uncertain Market? Gilead Sciences TheStreet.com
Jul-19-19 09:35AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2? Zacks
08:48AM  Gilead licensing three pre-clinical programs from Novartis MarketWatch
08:30AM  Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis Business Wire
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; insitro Inc.; Nurix Therapeutics, Inc.; Lyndra Therapeutics; and Carna Biosciences Inc., as well as the Chengdu Hi-tech Zone. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Option Exercise24.917,200179,31634,398Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Sale65.077,200468,50427,198Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJun 18Sale68.755,816399,85027,198Jun 20 04:52 PM
Cogan John FrancisDirectorMay 01Option Exercise22.022,86863,13957,728May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Option Exercise22.029,534209,89134,669May 02 06:48 PM
Cogan John FrancisDirectorMay 01Sale64.892,868186,11654,860May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Sale65.029,534619,93425,135May 02 06:48 PM
Cogan John FrancisDirectorApr 24Option Exercise22.022,70059,44157,560Apr 25 06:48 PM
Lofton Kevin EDirectorApr 24Option Exercise24.9113,208328,94543,332Apr 25 06:51 PM
Cogan John FrancisDirectorApr 24Sale62.612,700169,05454,860Apr 25 06:48 PM
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM
Cogan John FrancisDirectorApr 03Option Exercise22.022,70059,44157,560Apr 04 07:31 PM
Cogan John FrancisDirectorApr 03Sale66.742,700180,19854,860Apr 04 07:31 PM
Whitley Richard JamesDirectorApr 01Option Exercise22.029,534209,89134,669Apr 02 08:10 PM
Whitley Richard JamesDirectorApr 01Sale65.489,534624,25525,135Apr 02 08:10 PM
Cogan John FrancisDirectorMar 27Option Exercise22.022,70059,44157,560Mar 28 06:09 PM
Cogan John FrancisDirectorMar 27Sale64.142,700173,17854,860Mar 28 06:09 PM
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM
WILSON GAYLE EDirectorFeb 19Option Exercise0.0019,0680143,567Feb 20 08:06 PM
WILSON GAYLE EDirectorFeb 19Sale67.0819,0681,279,074124,499Feb 20 08:06 PM
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM